Table 1.
Baseline Characteristics
| Characteristics | Tesamorelin (N = 193) | Placebo (N = 148) | P-Value |
|---|---|---|---|
| Age (years) | 47.8 (±7.3) | 48 (±7.6) | 0.792 |
| Male (%) | 89.1 | 83.8 | 0.149 |
| Race (%) | 0.208 | ||
| White | 86 | 78.4 | |
| Black or African American | 9.3 | 11.5 | |
| Others | 4.6 | 10.2 | |
| Use of lipid lowering treatment (%) | 52.8 | 43.9 | 0.102 |
| Use of testosterone (%) | 24.9 | 17.6 | 0.105 |
| ART usage at baseline (%) | 0.642 | ||
| NRTI + NNRTI | 34.7 | 32.4 | |
| NRTI + NNRTI + PI | 9.3 | 6.8 | |
| NRTI + PI and no NNRTI | 47.7 | 48 | |
| NRTI alone | 4.1 | 6.1 | |
| Other | 4.1 | 6.8 | |
| CD4+ cell count (cells/mm3) | 636 (±319) | 604 (±270) | 0.664 |
| Body mass index (kg/m2) | 28.9 (±4.2) | 28.6 (±4.3) | 0.337 |
| Viral load (copies/mL) | 851 (±1,675) | 440 (±659) | 0.17 |
| Visceral adipose tissue area (cm2) | 197 (± 86) | 189 (± 85) | 0.38 |
| Insulin-like growth factor-1 | 152 (± 61.5) | 157(± 63) | 0.43 |
Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor